Elanco Animal Health Stock Price, News & Analysis

Elanco (NYSE:ELAN) has partnered with Splenda® and HATCH to launch Nutrition Secure Indianapolis, a comprehensive nutrition and wellness initiative targeting 250 Indianapolis families. The 12-month program combines weekly nutritious food deliveries with educational support to address food insecurity and promote better health outcomes.

The evidence-based initiative features weekly food boxes containing protein, produce, and low-sugar alternatives, alongside in-person education on healthy cooking and meal planning. The program is designed to be measurable and scalable, with built-in research components to assess its community impact and potential for expansion to other locations.

Elanco Animal Health (NYSE:ELAN) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference, scheduled for September 8-9, 2025. The company's leadership, including President and CEO Jeff Simmons and EVP and CFO Bob VanHimbergen, will engage in a fireside chat on September 9 at 8:30 a.m. ET.

Investors can access a live audio webcast through the "Events and Presentations" section of Elanco's investor website, with a replay available for a limited time after the event.

Elanco Animal Health (NYSE:ELAN) reported strong Q2 2025 results with revenue of $1.241 billion, up 5% year-over-year and 8% organic constant currency growth. The company achieved $11 million in reported net income and $131 million in adjusted net income.

Key performance metrics include Adjusted EBITDA of $238 million with a 19.2% margin, and EPS of $0.02 (reported) and $0.26 (adjusted). The company's net leverage ratio improved to 4.0x.

Based on strong performance, Elanco raised its 2025 guidance, now expecting revenue of $4.57-4.62 billion, increased innovation revenue target by $60 million to $720-800 million, and improved year-end net leverage ratio target to 3.8x-4.1x. The company plans to increase gross debt paydown to $500-550 million in 2025.

Elanco Animal Health (NYSE:ELAN) has received European Commission approval for Zenrelia™ (ilunocitinib), a once-daily oral JAK inhibitor for treating itching associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and older.

The approval follows a successful head-to-head study against market incumbent Apoquel, involving 338 dogs across 25 study sites in four countries, demonstrating Zenrelia's non-inferiority. The product is already available in Brazil, Canada, Japan, and the United States, with launch in EU markets expected before the end of Q3 2025.

Elanco Animal Health (NYSE:ELAN) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host a conference call at 8:00 a.m. Eastern time to discuss the results with investors, media, and the general public.

A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the event concludes.

Elanco Animal Health (NYSE:ELAN) has received USDA approval for TruCan™ Ultra CIV H3N2/H3N8, a groundbreaking canine influenza vaccine. The vaccine is the only ½ mL bivalent CIV vaccine offering protection against both H3N2 and H3N8 strains, achieving 100% virus neutralization against 33 current field isolates.

Key clinical achievements include zero lung lesions in vaccinated dogs post H3N2 challenge and proven reduction in viral shedding. The vaccine is particularly significant for high-risk breeds, including brachycephalic dogs, and completes Elanco's Tru Portfolio of vaccines featuring PureFil™ Technology. The product is now available for pre-order with shipping expected within 30 business days.

Neurizon Therapeutics has entered into an exclusive global licensing agreement with Elanco Animal Health (NYSE:ELAN) for Monepantel, the key ingredient in NUZ-001, their lead investigational therapy for ALS and other neurodegenerative diseases.

The agreement includes exclusive worldwide rights to Elanco's intellectual property, access to non-clinical studies and manufacturing data, and outlines terms for a future GMP-compliant Monepantel supply agreement. Financial terms include a nominal upfront fee, development milestone payments of $9.75 million for initial products and $5.2 million for subsequent products, sales milestones up to $65 million, and single-digit royalties on global net sales.

A formal supply agreement is expected to be finalized in H2 2025, which will provide Neurizon with a long-term source of GMP-compliant monepantel for clinical development and commercialization.

Elanco Animal Health (NYSE:ELAN) has released its 2024 Impact Report, introducing a new framework focused on four key communities: animals, customers, society, and employees. The company achieved significant milestones including $461 million in innovation revenue from new products like Zenrelia and Credelio Quattro, exceeding their target of $420-450 million.

Key achievements include becoming the #1 retail parasiticide dispenser in the U.S., launching Bovaer® for methane reduction in dairy cattle, and enrolling 11% of U.S. dairy herds in their UpLook sustainability database. The company demonstrated strong social impact through $400,000 in product donations, 26,000 volunteer hours, and improved employee engagement scores of 71% in Q1 2025.

Elanco Animal Health (ELAN) has received a positive opinion from the EU's Committee for Veterinary Medicinal Products for Zenrelia (ilunocitinib), a treatment for pruritus associated with allergic dermatitis and atopic dermatitis in dogs. The CVMP's recommendation, based on demonstrated quality, safety, and efficacy, sets the stage for EU marketing authorization within 60 days. Notably, Zenrelia is Elanco's fastest globalized product, with eight major regulatory approvals expected in just 18 months. The company has conducted a successful head-to-head non-inferiority study versus the market incumbent. Already available in Brazil, Canada, Japan, and the United States, Elanco plans to launch Zenrelia in the EU market before the end of Q3 2025, with additional approvals expected in Australia and the UK in 2025.